F-3 EX-FILING FEES 0001875091 N/A N/A 0001875091 1 2025-10-28 2025-10-28 0001875091 2025-10-28 2025-10-28 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

F-3

NeuroSense Therapeutics Ltd.

Table 1: Newly Registered and Carry Forward Securities

                                           
Line Item Type   Security Type   Security Class Title   Notes   Fee Calculation
Rule
  Amount Registered   Proposed Maximum Offering
Price Per Unit
  Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                           
Newly Registered Securities
Fees to be Paid   Equity   Ordinary shares, no par value per share   (1)   Other   333,334   $ 1.15   $ 383,334.10   0.0001381   $ 52.94
                                           
Total Offering Amounts:   $ 383,334.10         52.94
Total Fees Previously Paid:                
Total Fee Offsets:               0.00
Net Fee Due:             $ 52.94

__________________________________________
Offering Note(s)

(1) Pursuant to Rule 416(a) under the U.S. Securities Act of 1933, as amended (the “Securities Act”), the securities being registered hereunder also include such indeterminable number of additional securities as may from time to time be issued after the date hereof as a result of share splits, share dividends, recapitalizations or similar transactions.

Represents 333,334 ordinary shares, no par value per share (the “Ordinary Shares”), of NeuroSense Therapeutics Ltd. (the “Company”), issued in a private placement to the selling shareholder identified in the registration of which this exhibit forms a part. The Company will not receive any proceeds from the sale of its Ordinary Shares by the selling shareholder.

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act, as amended, based on the average of the equivalent high ($1.18) and low ($1.12) sales prices of the Ordinary Shares on the Nasdaq Capital Market on October 27, 2025.